Real-world studies: bridging the gap between trial-assessed efficacy and routine care

Daohong Chen

doi:10.7555/JBR.36.20220040

Volume 36 Issue 3

May 2022

Turn off MathJax

Article Contents

Article Navigation > The Journal of Biomedical Research > 2022 > 36(3): 147-154

Daohong Chen. Real-world studies: bridging the gap between trial-assessed efficacy and routine care[J]. The Journal of Biomedical Research, 2022, 36(3): 147-154. doi: 10.7555/JBR.36.20220040

Citation:

Daohong Chen. Real-world studies: bridging the gap between trial-assessed efficacy and routine care[J]. The Journal of Biomedical Research, 2022, 36(3): 147-154. doi: 10.7555/JBR.36.20220040

Daohong Chen. Real-world studies: bridging the gap between trial-assessed efficacy and routine care[J]. The Journal of Biomedical Research, 2022, 36(3): 147-154. doi: 10.7555/JBR.36.20220040

Citation:

Daohong Chen. Real-world studies: bridging the gap between trial-assessed efficacy and routine care[J]. The Journal of Biomedical Research, 2022, 36(3): 147-154. doi: 10.7555/JBR.36.20220040

PDF( 1772 KB)

Real-world studies: bridging the gap between trial-assessed efficacy and routine care

doi: 10.7555/JBR.36.20220040

Daohong Chen^,

Research Institute, Changshan Biochemical Pharmaceutical, Shijiazhuang, Hebei 050800, China

More Information

Corresponding author: Daohong Chen, Research Institute, Changshan Biochemical Pharmaceutical, North Head of Yinchuan Street, Zhengding New District, Shijiazhuang, Hebei 050800, China. Tel: +86-311-89190128, E-mail: daohong@hotmail.com
Received: 2022-03-02
Revised: 2022-03-20
Accepted: 2022-03-25

Published: 2022-05-10

Issue Date: 2022-05-27

Abstract

Abstract

Even though randomized controlled clinical trials (RCTs) have been accepted as the gold standard for official assessment of novel interventions, there is a substantial gap between the efficacy observed in RCTs and the impact on clinical practice and in terms of patient benefit. While real-world studies (RWS) are emerging to confer valuable complementing evidence in this regard and beyond, the evolving role of RWS is yet to be agreed. This article delineates an updated profile of RWS covering effectiveness verification, rare adverse effects discovery, indication repurposing, to name a few. RWS tends not only to improve the efficiency of clinical investigations for regulatory approval, but also optimizes the whole-life cycle evaluation of biomedical/pharmaceutical products.
- real-world evidence,
- therapeutic effectiveness,
- pharmacovigilance

FullText(HTML)

References(54)

References

[1]	Bothwell LE, Greene JA, Podolsky SH, et al. Assessing the gold standard-lessons from the history of RCTs[J]. N Engl J Med, 2016, 374(22): 2175–2181. doi: 10.1056/NEJMms1604593
[2]	Gray CM, Grimson F, Layton D, et al. A framework for methodological choice and evidence assessment for studies using external comparators from real world data[J]. Drug Saf, 2020, 43(7): 623–633. doi: 10.1007/s40264-020-00944-1
[3]	Monti S, Grosso V, Todoerti M, et al. Randomized controlled trials and real-world data: differences and similarities to untangle literature data[J]. Rheumatology, 2018, 57(57 Suppl 7): vii54–vii58. doi: 10.1093/rheumatology/key109
[4]	Beaulieu-Jones BK, Finlayson SG, Yuan W, et al. Examining the use of real-world evidence in the regulatory process[J]. Clin Pharmacol Ther, 2020, 107(4): 843–852. doi: 10.1002/cpt.1658
[5]	Chen D, Qi EY. Innovative highlights of clinical drug trial design[J]. Transl Res, 2020, 224: 71–77. doi: 10.1016/j.trsl.2020.05.007
[6]	Raschi E, Gatti M, Gelsomino F, et al. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance[J]. Target Oncol, 2020, 15(4): 449–466. doi: 10.1007/s11523-020-00738-6
[7]	Klonoff DC. The new FDA real-world evidence program to support development of drugs and biologics[J]. J Diabetes Sci Technol, 2020, 14(2): 345–349. doi: 10.1177/1932296819832661
[8]	U.S. Food and Drug Administration. Real-world evidence[EB/OL]. [2022-03-01]. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence.
[9]	Lou J, Kc S, Toh KY, et al. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward[J]. Int J Technol Assess Health Care, 2020, 36(5): 474–480. doi: 10.1017/S0266462320000628
[10]	European Medicines Agency. A vision for use of real-world evidence in EU medicines regulation[EB/OL]. [2022-03-01]. https://www.ema.europa.eu/en/news/vision-use-real-world-evidence-eu-medicines-regulation.
[11]	China Med Device. Implementation of guideline on real-world data[EB/OL]. [2022-03-01]. https://chinameddevice.com/implementation-of-guideline-on-real-world-data/.
[12]	Bolislis WR, Fay M, Kühler TC. Use of real-world data for new drug applications and line extensions[J]. Clin Ther, 2020, 42(5): 926–938. doi: 10.1016/j.clinthera.2020.03.006
[13]	Olender SA, Perez KK, Go AS, et al. Remdesivir for severe COVID-19 versus a cohort receiving standard of care[J]. Clin Infect Dis, 2021, 73(11): e4166–e4174. doi: 10.1093/cid/ciaa1041
[14]	Choy KT, Wong AYL, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro[J]. Antiviral Res, 2020, 178: 104786. doi: 10.1016/j.antiviral.2020.104786
[15]	Hoogwerf BJ, MacKenzie M, Sealls W, et al. Real-world glycemic lowering effectiveness of linagliptin among adults with type 2 diabetes by age, renal function, and race[J]. Diabetes Ther, 2020, 11(7): 1527–1536. doi: 10.1007/s13300-020-00841-x
[16]	Sehgal K, Bulumulle A, Brody H, et al. Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small-cell lung cancer[J]. Clin Lung Cancer, 2021, 22(3): e379–e389. doi: 10.1016/j.cllc.2020.05.028
[17]	Fadini GP, Sarangdhar M, De Ponti F, et al. Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors[J]. BMJ Open Diabetes Res Care, 2019, 7(1): e000725. doi: 10.1136/bmjdrc-2019-000725
[18]	Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data[J]. BMJ, 2017, 357: j1909. doi: 10.1136/bmj.j1909
[19]	Chen D. Heparin beyond anti-coagulation[J]. Curr Res Transl Med, 2021, 69(4): 103300. doi: 10.1016/j.retram.2021.103300
[20]	Shi C, Wang C, Wang H, et al. The potential of low molecular weight heparin to mitigate cytokine storm in severe COVID-19 patients: a retrospective cohort study[J]. Clin Transl Sci, 2020, 13(6): 1087–1095. doi: 10.1111/cts.12880
[21]	Shiomi M, Tanaka Y, Takada T, et al. Determining whether the effect of liraglutide on non-alcoholic fatty liver disease depends on reductions in the body mass index[J]. JGH Open, 2020, 4(5): 995–1001. doi: 10.1002/jgh3.12384
[22]	Nevado-Holgado AJ, Ribe E, Thei L, et al. Genetic and real-world clinical data, combined with empirical validation, nominate Jak-Stat signaling as a target for Alzheimer's disease therapeutic development[J]. Cells, 2019, 8(5): 425. doi: 10.3390/cells8050425
[23]	Madison R, Schrock AB, Castellanos E, et al. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling[J]. Lung Cancer, 2020, 148: 69–78. doi: 10.1016/j.lungcan.2020.07.033
[24]	Greenberg B, Peterson ED, Berger JS, et al. Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure[J]. Clin Cardiol, 2019, 42(2): 277–284. doi: 10.1002/clc.23140
[25]	Gluck E, Nguyen HB, Yalamanchili K, et al. Real-world use of procalcitonin and other biomarkers among sepsis hospitalizations in the United States: a retrospective, observational study[J]. PLoS One, 2018, 13(10): e0205924. doi: 10.1371/journal.pone.0205924
[26]	Raya PM, Blasco FJA, Hunt B, et al. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence[J]. Diabetes Obes Metab, 2019, 21(6): 1349–1356. doi: 10.1111/dom.13660
[27]	Martin EG, Schackman BR. Treating and preventing HIV with generic drugs - barriers in the United States[J]. N Engl J Med, 2018, 378(4): 316–319. doi: 10.1056/NEJMp1710914
[28]	Hübel K, Kron F, Lux MP. Biosimilars in oncology: effects on economy and therapeutic innovations[J]. Eur J Cancer, 2020, 139: 10–19. doi: 10.1016/j.ejca.2020.07.037
[29]	Mahumud RA, Kamara JK, Renzaho AMN. The epidemiological burden and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202, 005 infected patients: evidence from a systematic review and meta-analysis[J]. Infection, 2020, 48(6): 813–833. doi: 10.1007/s15010-020-01502-8
[30]	Jarcho JA, Ingelfinger JR, Hamel MB, et al. Inhibitors of the renin-angiotensin-aldosterone system and covid-19[J]. N Engl J Med, 2020, 382(25): 2462–2464. doi: 10.1056/NEJMe2012924
[31]	Wells CR, Townsend JP, Pandey A, et al. Optimal COVID-19 quarantine and testing strategies[J]. Nat Commun, 2021, 12(1): 356. doi: 10.1038/s41467-020-20742-8
[32]	Cattaneo D, Pasina L, Maggioni AP, et al. Drug-drug interactions and prescription appropriateness in patients with COVID-19: a retrospective analysis from a reference hospital in northern Italy[J]. Drugs Aging, 2020, 37(12): 925–933. doi: 10.1007/s40266-020-00812-8
[33]	Feagan BG, Marabani M, Wu JJ, et al. The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence[J]. Adv Ther, 2020, 37(11): 4491–4518. doi: 10.1007/s12325-020-01472-1
[34]	Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - final report[J]. N Engl J Med, 2020, 383(19): 1813–1826. doi: 10.1056/NEJMoa2007764
[35]	Chen D. Dual targeting autoimmunity and cancer: from biology to medicine[J]. J Clin Pharmacol, 2018, 58(8): 990–996. doi: 10.1002/jcph.1100
[36]	Trifirò G, Massari M, Da Cas R, et al. Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian cohort study of 43, 000 patients[J]. Drug Saf, 2020, 43(12): 1297–1308. doi: 10.1007/s40264-020-00994-5
[37]	Chen D, Zhang X. Cellular immunity augmentation in mainstream oncologic therapy[J]. Cancer Biol Med, 2017, 14(2): 121–128. doi: 10.20892/j.issn.2095-3941.2017.0022
[38]	Cavalla D. Using human experience to identify drug repurposing opportunities: theory and practice[J]. Br J Clin Pharmacol, 2019, 85(4): 680–689. doi: 10.1111/bcp.13851
[39]	Sharma D, Verma S, Vaidya S, et al. Recent updates on GLP-1 agonists: current advancements & challenges[J]. Biomed Pharmacother, 2018, 108: 952–962. doi: 10.1016/j.biopha.2018.08.088
[40]	Chen D, Goswami CP, Burnett RM, et al. Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle[J]. Cancer Res, 2014, 74(16): 4270–4281. doi: 10.1158/0008-5472.CAN-13-2817
[41]	Plant D, Barton A. Adding value to real-world data: the role of biomarkers[J]. Rheumatology (Oxford), 2020, 59(1): 31–38. doi: 10.1093/rheumatology/kez113
[42]	Chen D, Zhang X. Targeted therapy: resistance and re-sensitization[J]. Chin J Cancer, 2015, 34(11): 496–501. doi: 10.1186/s40880-015-0047-1
[43]	Roberts MH, Ferguson GT. Real-world evidence: bridging gaps in evidence to guide payer decisions[J]. Pharmacoecon Open, 2021, 5(1): 3–11. doi: 10.1007/s41669-020-00221-y
[44]	Gerlinger C, Evers T, Rassen J, et al. Using real-world data to predict clinical and economic benefits of a future drug based on its target product profile[J]. Drugs Real World Outcomes, 2020, 7(3): 221–227. doi: 10.1007/s40801-020-00203-w
[45]	Jones DS. History in a crisis - lessons for Covid-19[J]. N Engl J Med, 2020, 382(18): 1681–1683. doi: 10.1056/NEJMp2004361
[46]	Chen D. Dually efficacious medicine against fibrosis and cancer[J]. Med Sci (Basel), 2019, 7(3): 41. doi: 10.3390/medsci7030041
[47]	Mallappallil M, Sabu J, Gruessner A, et al. A review of big data and medical research[J]. SAGE Open Med, 2020, 8: 2050312120934839. doi: 10.1177/2050312120934839
[48]	Benchimol EI, Moher D, Ehrenstein V, et al. Retraction of COVID-19 pharmacoepidemiology research could have been avoided by effective use of reporting guidelines[J]. Clin Epidemiol, 2020, 12: 1403–1420. doi: 10.2147/CLEP.S288677
[49]	Naidoo P, Bouharati C, Rambiritch V, et al. Real-world evidence and product development: opportunities, challenges and risk mitigation[J]. Wien Klin Wochenschr, 2021, 133(15-16): 840–846. doi: 10.1007/s00508-021-01851-w
[50]	Curtis JR, Foster PJ, Saag KG. Tools and methods for real-world evidence generation: pragmatic trials, electronic consent, and data linkages[J]. Rheum Dis Clin North Am, 2019, 45(2): 275–289. doi: 10.1016/j.rdc.2019.01.010
[51]	Zariffa N, Russek-Cohen E. Vaccines after an emergency use authorization (EUA): modern evidence generation approaches[J]. Ther Innov Regul Sci, 2021, 55(4): 866–871. doi: 10.1007/s43441-021-00290-z
[52]	Brechbühl S, Bacher U, Jeker B, et al. Real-world outcome in the pre-CAR-T era of myeloma patients qualifying for CAR-T cell therapy[J]. Mediterr J Hematol Infect Dis, 2021, 13(1): e2021012. doi: 10.4084/MJHID.2021.012
[53]	O'Donnell JC, Le TK, Dobrin R, et al. Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes[J]. Future Oncol, 2021, 17(3): 333–347. doi: 10.2217/fon-2020-0591
[54]	Golob JL, Lugogo N, Lauring AS, et al. SARS-CoV-2 vaccines: a triumph of science and collaboration[J]. JCI Insight, 2021, 6(9): e149187. doi: 10.1172/jci.insight.149187